{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T02:51:43Z","timestamp":1794797503428,"version":"4.9.1"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Phenobarbital is frequently used in pediatric patients for treatment and prophylaxis of seizures. Pharmacokinetic data for this patient population is lacking and would assist in dosing decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective population pharmacokinetic analysis was designed for all pediatric patients &lt;19\u00a0years of age initiated on phenobarbital at our institution from January 2011 to June 2017. Patients were included if they were initiated on intravenous or enteral phenobarbital for treatment or prophylaxis of seizures and had a serum phenobarbital concentration monitored while an inpatient. Data collection included the following: age, weight, height, gestational age, core body temperature, serum creatinine, blood urea nitrogen, aspartase aminotransferase, alanine aminotransferase, urine output over the prior 12\u00a0hours, phenobarbital doses and serum concentrations, and potential drug\u2013drug interactions. Descriptive statistical methods were used to summarize the data. Pharmacokinetic analysis was performed with NONMEM and simulation was performed for doses of 10, 20, 30, and 40\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0dose<jats:sup>\u22121<\/jats:sup>, iv, followed by enteral doses of 3, 4, 5, and 6\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0d<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 355 patients (50.3% male, median gestational age 39\u00a0weeks (<jats:styled-content style=\"fixed-case\">interquartile range [IQR]<\/jats:styled-content> 35, 40), median age 0.28\u00a0years (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 0.06, 0.82). Median phenobarbital dose was enteral = 2.6 (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 1.9, 3.9) mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0dose<jats:sup>\u22121<\/jats:sup>; <jats:styled-content style=\"fixed-case\">intravenous<\/jats:styled-content> = 2.6 (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 2.2, 4.9) mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0dose<jats:sup>\u22121<\/jats:sup>) and mean serum concentration was 41.1\u00a0\u00b1\u00a023.9\u00a0mg\/L at median 6.5 (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 2.9, 11.1) hours after a dose. A one\u2010compartment proportional error model best fit the data where clearance and volume of distribution were allometrically scaled using fat\u2010free mass. Significant covariates included serum creatinine, postmenstrual age, and drug\u2013drug interactions on clearance, and age in years on volume of distribution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Phenobarbital dosing of 30\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0dose<jats:sup>\u22121<\/jats:sup>,<jats:styled-content style=\"fixed-case\">iv,<\/jats:styled-content> followed by 4\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0d<jats:sup>\u22121<\/jats:sup> had the highest probability of attaining a therapeutic concentration at 7\u00a0days. Postmenstrual age and drug\u2013drug interactions should be incorporated into dosing decisions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.14447","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T14:30:37Z","timestamp":1528900237000},"page":"1327-1333","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phenobarbital population pharmacokinetics across the pediatric age spectrum"],"prefix":"10.1111","volume":"59","author":[{"given":"Brady S.","family":"Moffett","sequence":"first","affiliation":[{"name":"Department of Pharmacy Texas Children's Hospital Houston TX USA"},{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindl M.","family":"Weingarten","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Texas Children's Hospital Houston TX USA"},{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Galati","sequence":"additional","affiliation":[{"name":"The Texas Medical Center Library Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Placencia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Texas Children's Hospital Houston TX USA"},{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Rodman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Texas Children's Hospital Houston TX USA"},{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Riviello","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Y.","family":"Kayyal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-010-0209-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00001"},{"key":"e_1_2_8_4_1","first-page":"31","article-title":"A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures","volume":"17","author":"Tulloch JK","year":"2012","journal-title":"J Pediatr Pharm Ther"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.05.026"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2005.00619.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01220.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0188-y"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303720"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150901110929"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12042"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1978.tb02428.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1975.tb03873.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0277-z"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e31825bbbc2"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197601030-00001"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2011.03536.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.060137"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-300538"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02662.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12291"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00030-9"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198005060-00001"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-3782(93)90108-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.4.639"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1542\/peds.43.1.114","article-title":"The effect of phenobarbital on diphenylhydantoin metabolism in children","volume":"43","author":"Buchanan RA","year":"1969","journal-title":"Pediatrics"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1992.tb01264.x"},{"key":"e_1_2_8_30_1","first-page":"315","article-title":"Interaction between plasma phenytoin and phenobarbital concentrations in epileptic patients","volume":"33","author":"Nishihara K","year":"1979","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"e_1_2_8_31_1","first-page":"203","article-title":"Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions","volume":"69","author":"Meyer UA","year":"1996","journal-title":"Yale J Biol Med"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.8.821"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:20:45Z","timestamp":1694910045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/epi.14447"],"URL":"https:\/\/doi.org\/10.1111\/epi.14447","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"2018-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}